Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia

Kami Maddocks-Christianson, Susan L Slager, Clive S. Zent, Megan Reinalda, Timothy G. Call, Thomas Matthew Habermann, Deborah A. Bowen, James Hoyer, Susan Schwager, Diane F Jelinek, Neil Elliot Kay, Tait D. Shanafelt

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Previous studies suggested that patients with chronic lymphocytic leukaemia (CLL) are at a three- to fivefold increased risk of developing a second lymphoproliferative disorder (LPD). This observational cohort study used the Mayo Clinic CLL Database to identify factors associated with developing a second LPD. A second LPD was identified in 26 (2.7%) of 962 CLL patients during a median follow-up of 3.3 years. Diffuse large B-cell lymphoma was the most common subtype of secondary LPD (12 of 26 cases). Patients previously treated for CLL had a trend toward higher prevalence of second LPD (4%) compared with previously untreated patients (2%; P = 0.053). More strikingly, patients treated with purine nucleoside analogues (PNA) had a significantly increased risk of subsequent second LPD (5.2%) compared with patients who had not received PNA (1.9%; P = 0.008). No statistically significant association was observed between risk of second LPD and other CLL characteristics (ZAP-70, CD38, IgVH mutation status or cytogenetic abnormalities). In this series, prior treatments with PNA or anthracyclines were the only significant factors associated with risk of developing a second LPD in patients with CLL. Physicians should strictly adhere to established criteria to initiate treatment for CLL patients who are not participating in clinical trials.

Original languageEnglish (US)
Pages (from-to)398-404
Number of pages7
JournalBritish Journal of Haematology
Volume139
Issue number3
DOIs
StatePublished - Nov 2007

Fingerprint

Second Primary Neoplasms
Lymphoproliferative Disorders
B-Cell Chronic Lymphocytic Leukemia
Purine Nucleosides
Lymphoma, Large B-Cell, Diffuse
Anthracyclines
Chromosome Aberrations
Observational Studies
Cohort Studies
Clinical Trials
Databases
Physicians
Mutation
Therapeutics

Keywords

  • Chronic lymphocytic leukaemia
  • Lymphoma
  • Prognostic parameters
  • Transformation
  • Treatment

ASJC Scopus subject areas

  • Hematology

Cite this

Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. / Maddocks-Christianson, Kami; Slager, Susan L; Zent, Clive S.; Reinalda, Megan; Call, Timothy G.; Habermann, Thomas Matthew; Bowen, Deborah A.; Hoyer, James; Schwager, Susan; Jelinek, Diane F; Kay, Neil Elliot; Shanafelt, Tait D.

In: British Journal of Haematology, Vol. 139, No. 3, 11.2007, p. 398-404.

Research output: Contribution to journalArticle

Maddocks-Christianson, Kami ; Slager, Susan L ; Zent, Clive S. ; Reinalda, Megan ; Call, Timothy G. ; Habermann, Thomas Matthew ; Bowen, Deborah A. ; Hoyer, James ; Schwager, Susan ; Jelinek, Diane F ; Kay, Neil Elliot ; Shanafelt, Tait D. / Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. In: British Journal of Haematology. 2007 ; Vol. 139, No. 3. pp. 398-404.
@article{9b556e60ae61461887a625be20c5b7e9,
title = "Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia",
abstract = "Previous studies suggested that patients with chronic lymphocytic leukaemia (CLL) are at a three- to fivefold increased risk of developing a second lymphoproliferative disorder (LPD). This observational cohort study used the Mayo Clinic CLL Database to identify factors associated with developing a second LPD. A second LPD was identified in 26 (2.7{\%}) of 962 CLL patients during a median follow-up of 3.3 years. Diffuse large B-cell lymphoma was the most common subtype of secondary LPD (12 of 26 cases). Patients previously treated for CLL had a trend toward higher prevalence of second LPD (4{\%}) compared with previously untreated patients (2{\%}; P = 0.053). More strikingly, patients treated with purine nucleoside analogues (PNA) had a significantly increased risk of subsequent second LPD (5.2{\%}) compared with patients who had not received PNA (1.9{\%}; P = 0.008). No statistically significant association was observed between risk of second LPD and other CLL characteristics (ZAP-70, CD38, IgVH mutation status or cytogenetic abnormalities). In this series, prior treatments with PNA or anthracyclines were the only significant factors associated with risk of developing a second LPD in patients with CLL. Physicians should strictly adhere to established criteria to initiate treatment for CLL patients who are not participating in clinical trials.",
keywords = "Chronic lymphocytic leukaemia, Lymphoma, Prognostic parameters, Transformation, Treatment",
author = "Kami Maddocks-Christianson and Slager, {Susan L} and Zent, {Clive S.} and Megan Reinalda and Call, {Timothy G.} and Habermann, {Thomas Matthew} and Bowen, {Deborah A.} and James Hoyer and Susan Schwager and Jelinek, {Diane F} and Kay, {Neil Elliot} and Shanafelt, {Tait D.}",
year = "2007",
month = "11",
doi = "10.1111/j.1365-2141.2007.06801.x",
language = "English (US)",
volume = "139",
pages = "398--404",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia

AU - Maddocks-Christianson, Kami

AU - Slager, Susan L

AU - Zent, Clive S.

AU - Reinalda, Megan

AU - Call, Timothy G.

AU - Habermann, Thomas Matthew

AU - Bowen, Deborah A.

AU - Hoyer, James

AU - Schwager, Susan

AU - Jelinek, Diane F

AU - Kay, Neil Elliot

AU - Shanafelt, Tait D.

PY - 2007/11

Y1 - 2007/11

N2 - Previous studies suggested that patients with chronic lymphocytic leukaemia (CLL) are at a three- to fivefold increased risk of developing a second lymphoproliferative disorder (LPD). This observational cohort study used the Mayo Clinic CLL Database to identify factors associated with developing a second LPD. A second LPD was identified in 26 (2.7%) of 962 CLL patients during a median follow-up of 3.3 years. Diffuse large B-cell lymphoma was the most common subtype of secondary LPD (12 of 26 cases). Patients previously treated for CLL had a trend toward higher prevalence of second LPD (4%) compared with previously untreated patients (2%; P = 0.053). More strikingly, patients treated with purine nucleoside analogues (PNA) had a significantly increased risk of subsequent second LPD (5.2%) compared with patients who had not received PNA (1.9%; P = 0.008). No statistically significant association was observed between risk of second LPD and other CLL characteristics (ZAP-70, CD38, IgVH mutation status or cytogenetic abnormalities). In this series, prior treatments with PNA or anthracyclines were the only significant factors associated with risk of developing a second LPD in patients with CLL. Physicians should strictly adhere to established criteria to initiate treatment for CLL patients who are not participating in clinical trials.

AB - Previous studies suggested that patients with chronic lymphocytic leukaemia (CLL) are at a three- to fivefold increased risk of developing a second lymphoproliferative disorder (LPD). This observational cohort study used the Mayo Clinic CLL Database to identify factors associated with developing a second LPD. A second LPD was identified in 26 (2.7%) of 962 CLL patients during a median follow-up of 3.3 years. Diffuse large B-cell lymphoma was the most common subtype of secondary LPD (12 of 26 cases). Patients previously treated for CLL had a trend toward higher prevalence of second LPD (4%) compared with previously untreated patients (2%; P = 0.053). More strikingly, patients treated with purine nucleoside analogues (PNA) had a significantly increased risk of subsequent second LPD (5.2%) compared with patients who had not received PNA (1.9%; P = 0.008). No statistically significant association was observed between risk of second LPD and other CLL characteristics (ZAP-70, CD38, IgVH mutation status or cytogenetic abnormalities). In this series, prior treatments with PNA or anthracyclines were the only significant factors associated with risk of developing a second LPD in patients with CLL. Physicians should strictly adhere to established criteria to initiate treatment for CLL patients who are not participating in clinical trials.

KW - Chronic lymphocytic leukaemia

KW - Lymphoma

KW - Prognostic parameters

KW - Transformation

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=34848904482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848904482&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2007.06801.x

DO - 10.1111/j.1365-2141.2007.06801.x

M3 - Article

C2 - 17910629

AN - SCOPUS:34848904482

VL - 139

SP - 398

EP - 404

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -